Marijuana Stocks CGRW
Search

canada - search results

If you're not happy with the results, please do another search

3 1510

The que to establish a Canadian legal marijuana business is getting unruly as applicants struggle to keep their dreams of selling med pot growing.

Written By: Matt Mernagh

This week licensed producer New Age Medical Solutions Inc. launched a lawsuit seeking a federal judge review their denial. http://www.cbc.ca/news/politics/medical-marijuana-applicant-takes-health-canada-to-court-1.2823362

 

The business waited a year and spent approximately one million dollars Canadian before Health Canada nixed their application. The company is part of a growing list of applicants who have spent a considerable sum and are in an approval quagmire.

 

Many are designated growers under the old program who have teamed up with investors and require to submit to extensive RCMP background checks. Long suspecting these growers are earning income from illegal sales – the RCMP is possibly using this as an opportunity to punish via slowness.

 

You’ll never prove beyond a shadow of a doubt they’re not moving paperwork quick enough because of political reasons, but they’re notoriously slow on regular background checks and blame staffing levels.

 

Having faced numerous constitutional challenges (including my own R v. Mernagh) – the agency responsible for overseeing licensed producers appears to have established their medical marijuana program with one eye on the courtroom.

Denied applicants may re-apply by fixing the identified problem – it’s alleged by Health Canada New Age Medical Solutions needs to hire a qualified quality assurance specialist.

 

Who is exactly qualified to be a quality assurance specialist for cannabis?

 

I have a book and held a court ordered exemption to grow cannabis – does that make me qualified.

 

A federal judge decision on that question could be years away and in the meantime the production facility sits empty.

 

Currently some 1,100 businesses have applied to sell medical marijuana to approximately 10,000 people. This number is growing as more doctors appear willing to sign paperwork. (I’m registered with Peace Naturals – which is not listed on TSX).

 

Health Canada claims about 291 businesses are in process of approval, but when will they be approved?

There’s a fairly impressive backlog of applicants and it includes a company headed by a former prime minister (John Turner) and another by a former Ontario provincial Liberal cabinet minister (George Smitherman.)

One would think a former prime minister would have some approval sway, but it doesn’t appear to be the case.

 

The snail’s pace approval is most likely somewhat intentional on government’s part. Unfortunately intentional government incompetence is a challenge to measure and if you’re one of 291 about to be approved – do you risk the agency’s ire by launching a lawsuit or speaking out.

 

To applicants and advocates it’s obvious pot hating Conservatives have slowed down the licensed producer application process to a God Bud couchlock.

 

Is this government incompetent business as usual or is an extra layer of personal dislike thrown in for good measure?

 

The Conservatives 2012 federal budget was described as “tough times for federal civil servants” with approximately 19,000 government employees given pink slips or retired out. The federal government shrank 4.8 percent and its effects are being felt everywhere, including medical marihuana approval.

 

Paper is not being pushed as quickly as applicants wish, probably because Health Canada doesn’t have adequate resources. Every business that qualifies will be granted a license, but Health Canada needs to have staff in place to manage all that Conservative created paperwork and oversight.

 

Will positive political muscle make a difference in moving paperwork?

 

The Mayor of Campbellton New Brunswick has come forward seeking the approval pace be quickened for Zenabis – which has promised a remarkable 400 weed jobs – when they open in his community. Campbellton’s been hard hit by unemployment and approximately 1400 people have applied for weed employment.

 

Is local Conservative MP Bernard Valcourt more interested in upholding prohibition or job creation?

It’s not uncommon for an MP to lobby on behalf of a business in their community that promises job creation – so why isn’t he going to bat for Zenabis?

The Conservative’s believe they are getting a two-for-one political ideological deal – smaller government and maintaining pot prohibition – but should be viewed as hampering job creation and investment.

Investors have tied up their cash flow in an investment that may or may not pay off. Many companies’ are bleeding money before they have even opened their doors. The approval uncertainty is finally causing investors to examine the possible payout more diligently.

Cannabis conspiracy theorist need look no further than Health Canada not having enough staff as to why more companies are not retailing medical cannabis than any other theory being floated.

 

0 448

Canada Will Tax Marijuana Just Like Tylenol

Cannabis Investment Expert Joins Supreme Pharmaceuticals

Supreme Pharma (SL-CSE) (SPRWF-OTCBB)

Interview with Brayden R. Sutton, Executive Vice President

VANCOUVER, British Columbia, Oct. 31, 2014 (GLOBE NEWSWIRE) — Tax Court Justice Campbell Miller just ruled that marijuana will be subject to federal Goods & Services Tax (GST) like Tylenol, cough drops and other over-the-counter drugs. The ruling confirms the government’s intent to legalise, regulate and tax medical marijuana in Canada. This is an important ruling, given that recent legislative changes have created a nascent medical marijuana industry in Canada that could be valued at over $1 Billion dollars in just a few years.

The creation of this newly commercialized industry creates a great opportunity for savvy investors to be early entrants and gain substantial returns. However, there are currently dozens of publically traded companies applying for permits to grow marijuana. The challenge is to pick the winning horse. With a space this cluttered it is instructive to see where the experts are placing their bets.

Supreme Pharmaceuticals (SL.V) (SPRWF) has just landed one of those experts, Mr. Brayden R. Sutton, President and CEO of CannabisHealth.com. Mr. Sutton joins Supreme as one of the most prominent cannabis investment experts in Canada, with nearly a decade spent covering the field from operational and public markets perspectives. As Executive Vice President of Supreme, Mr. Sutton will oversee facility design, operations, marketing, financing and business development.

“Being an early mover in the cannabis space, I was sought after and extended offers from almost every cannabis-related company in Western Canada as they all tried to position themselves in the marketplace,” stated Sutton in an exclusive interview with Financial Press, “Some of the offers were very tempting but I was truly looking for a company that checked all the boxes — the one that is providing Health Canada precisely what they’re looking for in the MMPR, one that could provide good value to their patients as well as their shareholders, and one that I felt will be around 10 years from now. I’m not interested in being a small player in the space or making a quick buck in a new sector – I want to take Supreme, the best company in the space in my opinion, to the finish line; and really set it up to be the dominant, low-cost, high-quality producer here in Canada.”

“Supreme received its ready-to-build permit back in January of this year,” stated Sutton, “Our facility has been fully retro-fitted to exceed the requirements of the Health Canada. It’s large, it’s secure, it’s in the right area, and we have local political support — on all levels. From local MP’s, the Mayor, and the town itself. We truly couldn’t be in a better town than Kincardine, Ontario. The 16-acre property, which houses the 7-acre facility, is located on the Bruce Energy Centre and has been independently appraised with an ‘in-use’ value of just under $22 million. We were fortunate enough to secure it for only $4.5m on very favourable terms. And frankly, we’ve yet to find a facility in Canada that is as more ideally suited to the MMPR as this one is, particularly when considering the local support, available skilled labour pool and heightened law enforcement presence due to our proximity to the Bruce Nuclear Power Plant. Our final phase of security is underway as we speak with Marcomm Systems Group and our Security Director, former OPP Drug Investigator Alan Roberton. We expect them to be complete by early November, at which point we will be ready to invite Health Canada to our facility for the inspection.”

Supreme’s Southern Ontario greenhouse is state-of-the-art, high tech facility utilizing advanced agricultural automation methods and applying them to the production of medical marijuana. It’s a 342,000 square foot greenhouse, which is the size of six NFL football fields. In addition, it is perfectly designed for medical marijuana production: it is built out of mould resistant tempered glass and steel, has sealed concrete flooring and is a “low top” design which reduces the facility’s heating and cooling requirements.

“We’ve employed Thaddeus Conrad, who is one of Canada’s leading producers of medical marijuana. Mr. Conrad is a leading breeder of innovative medical marijuana varieties, varieties which have earned him the title of North America’s most awarded marijuana breeder. As a result of this, Mr. Conrad is incredibly well-known under the name ‘Med-Man Brand,'” stated Sutton. “It is an honour to have him exclusively, as he brings with him decades of practical experience as well as a large and loyal patient following for early patient acquisition out of the gate. He is now collaborating with our team of greenhouse technicians, which includes one of Canada’s top agricultural experts who is a researcher at a well-known local University. At Supreme we have three elements: in our greenhouse we acquired the ideal facility, in Mr. Conrad we retained the best medical marijuana cultivator and breeder in the country and in our agricultural team we have some of the leading experts in pharmaceutical agricultural production. By doing this, we feel we will truly have the best value in the marketplace to offer our clients top-quality medicine, consistently, at a very affordable price.”

Sutton stresses that Supreme’s facility is far from a “grow-op” – it’s a high-tech pharmaceutical-grade greenhouse that is ideally suited for medical marijuana production. Health Canada has stated numerous times that it wants a regulated, standardized, automated production system that will turn out a consistent, and most importantly, safe product that meets their very stringent quality assurance measure, and we intend to give them just that. Supreme’s facility provides that; a large volume producer, with a design and operational plan designed for standardization and safety and sufficient economies of scale to implement robust quality control and quality assurance procedures. Supreme also benefits from favourable energy rates, due to the proximity of the local power plant, and most importantly the sun, which will provide up to 60% of the energy needed to produce high-quality medical marijuana.

Supreme is quickly checking off items required to be implemented prior to inspection: the razor-wire topped security fence is in place, the level-9 vault has been installed, the growing areas have been constructed and extensive electronic security and surveillance systems are being implemented right now. Once the final security systems are in place and the production areas are finalized, Supreme will be ready for its inspection by Health Canada. Mr. Sutton states that Supreme anticipates being ready for the inspection by mid November.

“What is unique about our greenhouse is that there is a large concrete structure in the center which houses the vault and high security processing areas. The greenhouse itself provides 4 quadrants of actual growing area, 340k sq. ft. in total, with our controlled rooms being 3,520 sq. ft. each. Even the flow of the building is ideal, in terms of the steps required from the trimming of the plant, to the shipping of it out the door. Employee and product flow has been meticulously designed to increase efficiency and reduce the risk of contamination. There will be an assembly line of sorts, where the production staff will be sealed off from the rest of the operation, allowing them to move the product down the line, while not interfering with anyone who is hands on inside of the actual grow space.”

Supreme Pharma has just raised $2.6M from a recent financing and currently undertaking an additional raise. And is more than capitalized to go right into production and start fulfilling patient orders.

Through economy of scale, Sutton anticipates drastically reducing the market price of cannabis.

“Our goal is to use the extensive medical marijuana expertise our management team has to shake up the marketplace. We will achieve this by using a gradient pricing model, which allows us to target multiple market segments while maintain transparency and credibility with our patients and doctors. We will sell the majority of our products for around $5.00 per gram. From there, premium parts of each crop will be given the ‘royal treatment’ and sold for upwards of $8.00 per gram, to those who can afford it. On the other end of the spectrum, smaller buds and shake will be sold for $2 and $1 respectively. Its all good medicine, but you have to be honest with the doctors and patients about what you are providing. The low cost options are also essential because a large proportion of our patients are very cost-sensitive, and currently expend a great deal of their monthly income on their medicine. The low cost model also improves our ability to pressure insurance providers to provide benefits for medical marijuana.”

Sutton is also very focused on patient acquisition, “The part of the business that many companies are struggling to find an effective way. We are very happy to say that we have roughly 500 patients on stand-by, with many more contacting us daily.” Mr. Sutton reports these patients come from existing relationships held by Supreme’s management team, as well as many individuals living or working near the facility, “and that has all been organic so far, as we’ve not yet had to pay one dime for patients. I have some long-standing relationships with cannabis-friendly physicians, and our hope is to be able to work closely with them, to better educate the public in what is very much going to be an industry driven part of Canada’s Health Care.” This is a benefit for Supreme, as this early patient acquisition is achieved without expending capital to acquire initial patients. In addition, Mr. Sutton reports that Supreme has had strong interest from a number of potential producers to provide marijuana on a wholesale basis. “This is the perfect market opportunity for Supreme, where we can supply others with wholesale marijuana and increase our revenues faster than we can acquire our own patients. Also, when you consider that less of an expense is required to sell wholesale medical marijuana as compared to retailing to individual patients, the profitability of our wholesale division is on par with the retail side.”

“We are in the final stages of completing of the requirements for our Southern Ontario growing facility,” stated Sutton, “I have a decade of experience in this field that tells me when something is going to work. Supreme Pharmaceuticals is that something. In my opinion, it is a question of ‘when’ not ‘if’ it becomes one of the dominant providers in this exciting new sector.”

Supreme Pharmaceuticals is currently trading at $.47 with a market cap of $28 million.

Legal Disclaimer/Disclosure: A fee has been paid for the production and distribution of this Report. This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. No information in this article should be construed as individualized investment advice. A licensed financial advisor should be consulted prior to making any investment decision. Financial Press makes no guarantee, representation or warranty and accepts no responsibility or liability as to its accuracy or completeness. Expressions of opinion are those of the authors only and are subject to change without notice. Financial Press assumes no warranty, liability or guarantee for the current relevance, correctness or completeness of any information provided within this article and will not be held liable for the consequence of reliance upon any opinion or statement contained herein or any omission. Furthermore, we assume no liability for any direct or indirect loss or damage or, in particular, for lost profit, which you may incur as a result of the use and existence of the information, provided within this article.

Also, please note that republishing of this article in its entirety is permitted as long as attribution and a back link to FinancialPress.com are provided. Thank you.

Contact:

Supreme Pharmaceuticals
Suite #430, 580 Hornby Street
Vancouver, BC
V6C 3B6
Email: info@supremepharmaceuticals.com
Phone: 604.674.2191

0 127

Affinor Growers Closes Exclusive Sublicense Agreement With Native American Communities in the U.S.

Recent Marijuana Ruling Could Lead to Indian Tribes Becoming Among America’s Biggest Producers

MONTREAL, CANADA–(Marketwired – Dec 18, 2014) – Affinor Growers (CSE:AFI)(1AF.F)(RSSFF) (“Affinor” or the “Corporation) announced today that it has closed the Definitive Agreement of the previously announced LOI on November 4, 2014 with North Country Natural Solutions LLC (“North Country”) and Iroquois Consulting Group LLC (“Iroquois”) in New-York State. It represents a $500,000.00 sublicensing agreement and 5% royalty on the net sales on the food production. Additionally North Country and Iroquois will offer consulting services to represents exclusively Affinor with all the Native Communities in the United States in the agriculture and cannabis sectors with the objective to become leader and a model in both industry.

Native American tribes across the U.S. learned on Thursday, December 11th, that the U.S. Department of Justice will allow tribes to grow and sell marijuana on their lands if they follow the federal guidelines established for states that have legalized the drug.

Affinor is sublicencing his vertical farming technology to North Country and Iroquois to have them grow, produce, distribute, sell, market and commercialise the products related to the Agriculture in New-York States. In the mean time, North Country and Iroquois will represents Affinor with all the Native American Tribes across the United States to developp affiliations and sustainability to produce healthy food using vertical growing technology and high quality cannabis using different technics.

Kelly Mitchell commented, “Iroquois and North Country Natural Solutions are thrilled to be afforded the opportunity to work with Affinor to bring its farming technology and expertise in the agriculture and medical marijuana industry to First Nation communities. We foresee this agreement with Affinor and ICG and NCNS playing a substantial role in providing long overdue economic development to Native communities throughout North America.”

Nick Brusatore, Affinor Chairman, commented, “This is a very proud moment for myself and Affinor and a very exciting time for the First Nation people in the USA. Affinor’s vision has always been to help and assist the First Nation to mass produce food for their people to help with the diabetes and to consult and design what is needed to get them ready for the tobacco industry with the marijuana looming federally now. We look forward to assisting the first nation communities and enabling Affinor to advise them as to how to utilize our safe, high quality agricultural and vertical farming technologies to stand up state of the art production facilities. Myself having a wife and four daughters being Status Natives in Canada and members of the Squamish Nation in Vancouver has driven me personally to want this for all First Nation people and I am committed to them to make this happen.”

About Affinor Growers Inc.

Affinor Growers is a diversified publicly traded company on the Canadian Securities Exchange under the symbol (“AFI”). Affinor is focused on growing high quality crops such as romaine lettuce, spinach, strawberries and high quality medical Marijuana. Affinor is committed to becoming a pre-eminent grower, using exclusive vertical farming techniques.

On Behalf of the Board of Directors

AFFINOR GROWERS INC.

“Sebastien Plouffe”, President & CEO

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release

FORWARD LOOKING INFORMATION

This News Release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com. This News Release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Contact:
Contact Information
Investor Relations:
Scott Greiper
Secure Strategy Group, LLC
212-333-0257
sgreiper@securesg.com
Contact Information, spokesperson
Affinor Growers
Nick Brusatore, Executive Chairman
(604) 356-0411
nbrusatore@gmail.com
www.affinorgrowers.com

0 94

Happy Holidays from Surna!

BOULDER, CO / December 18, 2014 / Thanks for a green 2014! Happy Holidays and Happy New Year from the entire Surna team. We look forward to growing with you in 2015!

About Surna, Inc.:

Surna, Inc. (www.surna.com) engineers, manufactures and installs commercial agricultural equipment to cannabis cultivation facilities. Surna acquires scalable operating companies in the cannabis sector and expands them by incorporating its proprietary grow technology and comprehensive support systems.

Surna is headed by technology industrialist and robotics engineer Tom Bollich, co-founder of the highly-publicized gaming Company Zynga. The Company drew national attention when its market valuation quickly surpassed $10 billion.

Surna’s nine-man engineering team sidesteps technological obsolescence by perpetually developing improved cultivation systems. This engineering advantage provides the Company with financial access to the entire cannabis economy. Surna continuously creates highly adaptivetechnology and software that satisfies the numerous, highly-specific and essential demands of the cannabis industry. Because cannabis remains federally illegal, Surna’s operations exclude the production or sale of marijuana. Interested parties are advised to read Surna’s Statement About Cannabis Markets below.

Safe Harbor Statement

This news release contains statements that involve expectations, plans or intentions (such as those relating to future business or financial results, new features or services, or management strategies) and other factors discussed from time to time in the Company’s Securities and Exchange Commission filings. These statements are forward-looking and are subject to risks and uncertainties, so actual results may vary materially. You can identify these forward-looking statements by words such as “may,” “should,” “expect,” “anticipate,” “believe,” “estimate,” “intend,” “plan” and other similar expressions. Our actual results, such as the Company’s ability to finance, complete and consolidate acquisition of IP, assets and operating companies, could differ materially from those anticipated in these forward-looking statements as a result of certain factors not within the control of the company such as a result of various factors, including future economic, competitive, regulatory, and market conditions. The company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. The company disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

Statement About Cannabis Markets

The use, possession, cultivation, and distribution of cannabis is prohibited by federal law. This includes medical and recreational marijuana. Although certain states have legalized medical and recreational cannabis, companies and individuals involved in the sector are still at risk of being prosecuted by federal authorities. Further, the landscape in the cannabis industry changes rapidly. What was the law last week is not the law today and what is the law today may not be the law next week. This means that at any time the city, county, or state where cannabis is permitted can change the current laws and/or the federal government can supersede those laws and take prosecutorial action. Given the uncertain legal nature of the cannabis industry, it is imperative that investors understand that the cannabis industry is a high risk investment. A change in the current laws or enforcement policy can negatively affect the status and operation of our business, require additional fees, stricter operational guidelines and unanticipated shut downs.

At the Company
David Traylor
Chief Business Officer
(303) 993-5271
david.traylor@surna.com

Investor Relations
David Kugelman
Atlanta Capital Partners, LLC
(404) 856-9157
(866) 692-6847 Toll Free – U.S. And Canada

SOURCE: Surna Inc.

 

0 86

Lexaria Changes Brand Name and Clarifies Hemp Environment

Lexaria Announces Name Change of PoViva Tea to ViPova(TM) Tea, and Provides Information on Hemp-Based Industry

Kelowna, BC / ACCESSWIRE / December 17, 2014 / Lexaria Corp. (LXRP) (CSE:LXX) (the “Company”) announces that effective immediately, it’s 51%-owned company formerly known as PoViva Tea, will now operate with the trade name of ViPova(TM) Tea. Selling our products under the name of ViPova(TM) is a branding strategy undertaken to ensure long term protection of intellectual rights.

The name change does not affect ownership, operational or any other material issues. However the name change has delayed the product launch by 1-2 weeks, so that ViPova(TM) Tea is now expected to be available to be ordered by consumers around the first week of January.

Both Lexaria and ViPova(TM)also wish to clarify some important distinctions about the Cannabidiol(CBD)-from-hemp industry within which ViPova(TM) operates. Hemp based CBD is legal in all 50 states, as are hemp-based food products that can be purchased from national retailers like Whole Foods or Costco, and many regional food stores. Popular hemp food products include hemp cereal, seeds, milk, and oil.

Hemp based products contain very low thresholds of Tetrahydrocannabinol (THC) below government-imposed limits of less than 0.3%. At the same time, the CBD within hemp is NOT psychoactive and does not create feelings of euphoria. Hemp is grown legally in countries like Canada, England, New Zealand and parts of Europe, and is legally imported into the USA from these and other countries.

ViPova(TM) uses only legal CBD oil extracts, grown from legal hemp in nations where it is legal to do so, in ViPova(TM)-branded tea. ViPova(TM) uses its patent-pending process to infuse concentrated amounts of CBD within lipids in its tea, providing more bioactivity and comfort to the body during the absorption process. Only ViPova(TM) has this ground-breaking technology for CBD/lipid infusion.

ViPova(TM) has not entered, and has no plans to enter, the medical marijuana market whether located within the USA or in any other country. ViPova(TM) is building a new company and product line focused exclusively on legal CBD products, which at this time are available only within the United States.

About Lexaria

Lexaria’s shares are quoted in the USA with symbol LXRP and in Canada with symbol LXX. The company searches for projects that could provide potential above-market returns.

To learn more about Lexaria Corp. visit www.lexariaenergy.com.

FOR FURTHER INFORMATION PLEASE CONTACT:

Lexaria Corp.
Chris Bunka
Chairman & CEO
(250) 765-6424

FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Access to capital, or lack thereof, is a major risk and there is no assurance that the Company will be able to raise required working capital. Current oil and gas production rates may not be sustainable and targeted production rates may not occur. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that the medical marijuana, CBD sector, or alternative health businesses will provide any benefit to Lexaria, or that the Company will experience any growth through participation in these sectors. There is no assurance that existing capital is sufficient for the Company’s needs or that it will need to attempt to raise additional capital. There is no assurance that any cannabinoid-based product will promote, assist, or maintain any beneficial human health conditions whatsoever. No statement herein has been evaluated by the Food and Drug Administration (FDA). ViPova(TM) products are not intended to diagnose, treat, cure or prevent any disease.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

SOURCE: Lexaria Corp.

 

0 153

Surna Selected to Present at Investor-Focused Cannabis Investor Webcast

Boulder, CO / ACCESSWIRE / December 16, 2014 / Surna Inc. (SRNA), an engineering, manufacturing, and installation Company specializing, where state law permits, in commercial indoor cannabis cultivation technology, has been selected to participate in the Cannabis Investor Webcast on December 18, 2014, at 11:00 a.m. EST. Surna CEO Tom Bollich will speak live and detail the Company’s engineering and tech-based approach to cannabis cultivation.

“This webcast is a great opportunity for our shareholders to gain a better understanding of the technology our engineering team has developed, as well as where Surna is heading. We believe our Company and our disruptive technology are well positioned to advance the entire cannabis industry,” said Bollich. “Cannabis cultivation is becoming increasingly technical, so Surna has assembled some very ambitious engineers and put them to work under one roof. Our engineering collective is motivated, diverse and capable of creating technologies that are years ahead of their time.”

Surna’s keystone product, a water-cooled climate control system, is an energy efficient alternative to traditional HVAC. In Q1 2015, Surna will release its water-cooled reflector, which will offer up to 50% energy savings on climate control, when paired with Surna’s chiller. Behind lighting, climate control is the second largest energy cost in a grow operation.

The webcast will include presentations and Q&A sessions from Surna and nine additional private and public cannabis related companies including Viridian Capital and Research and Lexaria Corp. over the course of the day. Interested cannabis investors can register for the webcast at no charge at www.cannawebcast.com.

About Surna, Inc.:

Surna, Inc. (www.surna.com) engineers, manufactures and installs commercial agricultural equipment to cannabis cultivation facilities. Surna acquires scalable operating companies in the cannabis sector and expands them by incorporating its proprietary grow technology and comprehensive support systems.

Surna is headed by technology industrialist and robotics engineer Tom Bollich, co-founder of the highly-publicized gaming Company Zynga. The Company drew national attention when its market valuation quickly surpassed $10 billion.

Surna’s nine-man engineering team sidesteps technological obsolescence by perpetually developing improved cultivation systems. This engineering advantage provides the Company with financial access to the entire cannabis economy. Surna continuously creates highly adaptive technology and software that satisfies the numerous, highly-specific and essential demands of the cannabis industry. Because cannabis remains federally illegal, Surna’s operations exclude the production or sale of marijuana. Interested parties are advised to read Surna’s Statement About Cannabis Markets below.

About Cannabis Investor Webcast:

The Cannabis Investor Webcast is held monthly on the fourth Tuesday of the month. The webcast includes 45-minute live presentations and Q&A by CEO’s and CFO’s of privately-held and publicly traded cannabis companies. The webcast audience includes international and domestic cannabis entrepreneurs, individual and institutional investors, analysts, media, and consumers. The Cannabis Investor Webcast offers cannabis companies a convenient and inexpensive way to increase liquidity, awareness and exposure. In addition, the Cannabis Investor Webcast gives cannabis entrepreneurs, individual and institutional investors, analysts, media, and consumers a convenient and inexpensive way to research privately-held and publicly traded cannabis companies.

Safe Harbor Statement

This news release contains statements that involve expectations, plans or intentions (such as those relating to future business or financial results, new features or services, or management strategies) and other factors discussed from time to time in the Company’s Securities and Exchange Commission filings. These statements are forward-looking and are subject to risks and uncertainties, so actual results may vary materially. You can identify these forward-looking statements by words such as “may,” “should,” “expect,” “anticipate,” “believe,” “estimate,” “intend,” “plan” and other similar expressions. Our actual results, such as the Company’s ability to finance, complete and consolidate acquisition of IP, assets and operating companies, could differ materially from those anticipated in these forward-looking statements as a result of certain factors not within the control of the company such as a result of various factors, including future economic, competitive, regulatory, and market conditions. The company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. The company disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

Statement About Cannabis Markets

The use, possession, cultivation, and distribution of cannabis is prohibited by federal law. This includes medical and recreational marijuana. Although certain states have legalized medical and recreational cannabis, companies and individuals involved in the sector are still at risk of being prosecuted by federal authorities. Further, the landscape in the cannabis industry changes rapidly. What was the law last week is not the law today and what is the law today may not be the law next week. This means that at any time the city, county, or state where cannabis is permitted can change the current laws and/or the federal government can supersede those laws and take prosecutorial action. Given the uncertain legal nature of the cannabis industry, it is imperative that investors understand that the cannabis industry is a high risk investment. A change in the current laws or enforcement policy can negatively affect the status and operation of our business, require additional fees, stricter operational guidelines and unanticipated shut downs.

At the Company
David Traylor
Chief Business Officer
(303) 993-5271
david.traylor@surna.com

Investor Relations
David Kugelman
Atlanta Capital Partners, LLC
(404) 856-9157
(866) 692-6847 Toll Free – U.S. And Canada

SOURCE: Surna Inc.

0 176

Form 10-Q for NEUTRA CORP.

15-Dec-2014

Quarterly Report

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONSOverview

Neutra Corp. is a development stage company incorporated in Florida on January 11, 2011 to market and participate in the Nutraceutical space by bringing products derived from all natural and organic origins. Along with participating in the actual nutraceutical products, we plan to research and bring new technology to the Nutraceutical space. Nutraceutical natural medicine is an alternative system that focuses on natural remedies and the body’s vital ability to heal and maintain itself. One of the nutraceutical sub-markets is the new thriving medical cannabis market, in which we will be doing our due diligence and participating. We intend to entrust the manufacturing to a nutraceutical contractor to private label all of our products and to sell them under our unique brand. We have established a fiscal year end of January 31.

On January 11, 2013, the Company executed an Option Agreement with Purlife Distributors Inc, and authorized distributor of DrivePur and Purteq products in Canada, (hereafter referred to as “Purlife”. Purlife owns rights to market, in Canada, environmentally friendly, sustainable, and long-lasting antimicrobial solutions for indoor and outdoor surfaces. The Option Agreement shall be for a period of ninety (90) days beginning from the date of the agreement. The Company will pay Purlife a $5,000 non-refundable payment. Under the option agreement, the Company, will have the right to conduct a due diligence review of Purlife with complete access to data, patent applications, financial statements and other pertinent information. From the Option Agreement, the Company was able to form a Joint Venture with Purlife on February 1, 2013.

On February 1, 2013, the Company entered into a Joint Venture Agreement with Purlife. The Joint Venture was created towards developing and marketing the brands represented by Purlife. Purlife will execute the business plan or other programs as agreed to as well as make any necessary disbursements on behalf of the Joint Venture, and collect and distribute profits in accordance with the ownership percentages. The Joint Venture will allocate profits for a period of 3 years with the Company receiving 10% and the Joint Venture receiving 90%. All loss and disbursements incurred by Purlife in acquiring, holding, and protecting the business interest and the net profits shall, during the period of the venture be paid by Purlife. All losses incurred by the Parties will be limited to their financial contribution to the Joint Venture. The Company will provide consulting to the Joint Venture and participate in strategic and operation decisions as required.

The Company will be a way of providing start up and operating expenses such as to facilitate the completion of the undertaking of the Business.

During the year ended January 31, 2014, the Company paid a total of $150,000 to fund the cash flow requirements as set forth in an approved budget prepared by Purlife. These payments are included in general and administrative expense on the statement of operations. The Company has no further obligation to continue funding.

On May 30, 2013, the Company entered into a joint venture agreement with Field of View Technologies, LLC. (the “Field of View JV”). The purpose of the Field of View JV is to develop, produce, and market a new cannabis inhalation delivery system. Under the terms of the agreement, the Company will provide funding for the project and provide consulting services to the Field of View JV. Field of View Technologies, LLC will develop the product and manage the joint venture. In exchange, the Company will receive 25% of the profit on all inhalation cannabinoid delivery systems for a period of 36 months. The Company has committed to fund $175,000 of the costs of the Field of View JV.

On June 5, 2013, the Company entered into a joint venture agreement with Vertigo Technologies, LLC. (the “Vertigo JV”). The purpose of the Vertigo JV is to develop post-production equipment in the horticultural market. Under the terms of the agreement, the Company will provide funding for the project. Vertigo Technologies, LLC will develop the product and manage the joint venture. In exchange, the Company will receive 30% of the profit on all cannabinoid post-production technology products for a period of 36 months. The Company has committed to fund $85,000 of the costs of the Vertigo JV.

On August 25, 2013, the Company entered into a joint venture agreement with Second Wave Ventures, LLC. (the “Second Wave JV”). The purpose of the Second Wave JV is to develop, produce and market nutraceutical products and deliver systems. Under the terms of the agreement, the Company will provide funding for the operations of the joint venture. In exchange, the Company will receive 30% of the profits on all products and delivery systems within the nutraceutical market. The Company has committed to fund $85,000 under the Second Wave JV, which will be paid in weekly payments of $5,000.

- 15 -


On August 27, 2013, the Company entered into a joint venture agreement with Surface to Air Solutions, LLC. (the “S2O2 JV”). The purpose of the S2O2 JV is to work together to develop, produce, and market new services and products that are utilized within the market of horticultural production. Under the terms of the agreement, the Company will provide management, marketing, and other consulting services to the S2O2 JV. In addition, the Company will re-design the web marketing material for the joint venture. NTRR will fund up to $100,000 of the operating costs of the S2O2 JV at its discretion. After an initial payment of $10,000 on September 1, 2013, funding will be made in weekly installments of $7,500. In exchange, NTRR will receive 25% of the profits on all products and services that are used within the horticultural market.

On February 11, 2014, the Company acquired Diamond Anvil Designs, a developer of smoke-free nutraceutical delivery systems. Diamond Anvil Designs is a development stage startup vapor pen company that is designing an all-purpose vapor pen. Currently most vapor pens are manufactured only to be used for tobacco, so we feel this an underdeveloped area of the market.

In their audit report dated March 15, 2014; our auditors have expressed an opinion that substantial doubt exists as to whether we can continue as an ongoing business. If we do not raise additional capital within twelve months, we may be required to suspend or cease the implementation of our business plan.

We have not generated any revenues to date and our activities have been limited to developing our business plan, developing and launching our website, research and development of products and trial testing of our initial formulations. We will not have the necessary capital to fully develop or execute our business plan until we are able to secure additional financing. There can be no assurance that such financing will be available on suitable terms. We need to raise an additional $400,000 to implement our business plan over the next twelve months. Our current cash on hand is insufficient to commercialize our products or fully develop our business strategy. If we are unable to raise adequate additional funds or if those funds are not available on terms that are acceptable to us, we will not be able to execute our business plan and we may cease operations.

We have no revenues; have incurred losses since inception, have been issued a going concern opinion from our auditors and rely upon the sale of our securities and borrowing to fund operations.

Critical Accounting Policies

We prepare our Consolidated financial statements in conformity with GAAP, which requires management to make certain estimates and apply judgments. We base our estimates and judgments on historical experience, current trends, and other factors that management believes to be important at the time the condensed Consolidated financial statements are prepared. On a regular basis, we review our accounting policies and how they are applied and disclosed in our condensed Consolidated financial statements.

While we believe that the historical experience, current trends and other factors considered support the preparation of our condensed consolidated financial statements in conformity with GAAP, actual results could differ from our estimates and such differences could be material.

For a full description of our critical accounting policies, please refer to Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report for the year ended January 31, 2014 on Form 10-K.

Results of Operations

Nine months ended October 31, 2014 compared to the nine months ended October 31, 2013.

General and Administrative Expenses

We recognized general and administrative expenses in the amount of $514,021 and $705,532 for the nine months ended October 31, 2014 and 2013, respectively. The decrease is due to a $230,000 reduction in spending toward profit participation agreements.

Interest Expense

Interest expense increased from $140,124 for the nine months ended October 31, 2013 to $806,102 for the nine months ended October 31, 2014. Interest expense for the nine months ended October 31, 2014 included amortization of discount on convertible notes payable in the amount of $737,365, compared to $119,957 for the comparable period of 2013. The remaining amount is the result of the Company entering into interest-bearing convertible notes payable.

- 16 -


Loss on Acquisition

During the nine months ended October 31, 2014, we incurred a $100,000 loss on the acquisition of Diamond Anvil. We had no acquisition losses during the nine months ended October 31, 2013.

Net Loss

We incurred a net loss of $1,420,123 for the nine months ended October 31, 2014 as compared to $845,656 for the comparable period of 2013. The increase in the net loss was primarily due to increased interest expense and the loss on our Diamond Anvil acquisition, counteracted by the reduction in profit participation agreements.

Three months ended October 31, 2014 compared to the three months ended October 31, 2013.

General and Administrative Expenses

We recognized general and administrative expenses in the amount of $164,003 and $273,511 for the three months ended October 31, 2014 and ended 2013, respectively. This was mainly due to a $162,500 decrease in our contribution toward profit participation agreements.

Interest Expense

Interest expense increased from $76,257 for the three months ended October 31, 2013 to $357,835 for the nine months ended October 31, 2014. Interest expense for the three months ended October 31, 2014 included amortization of discount on convertible notes payable in the amount of $338,962 compared to $61,620 for the comparable period of 2013. The remaining amount is the result of the Company entering into interest-bearing convertible notes payable.

Net Loss

We incurred a net loss of $531,838 for three nine months ended October 31, 2014 as compared to $349,768 for the comparable period of 2013. The increase in the net loss is due to the increases in interest expense, offset by the reduction in general and administrative expenses discussed above.

Liquidity and Capital Resources

At October 31, 2014, we had cash on hand of $9,146. The company has negative working capital of $387,462 . Net cash used in operating activities for the nine months ended October 31, 2014 was $456,936. Cash on hand is adequate to fund our operations for less than one month. We do not expect to achieve positive cash flow from operating activities in the near future. We will require additional cash in order to implement our business plan. There is no guarantee that we will be able to attain fund when we need them or that funds will be available on terms that are acceptable to the Company. We have no material commitments for capital expenditures as of October 31, 2014.

Additional Financing

Additional financing is required to continue operations. Although actively searching for available capital, the Company does not have any current arrangements for additional outside sources of financing and cannot provide any assurance that such financing will be available.

Off Balance Sheet Arrangements

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

 

0 127

Easton Pharmaceuticals Releases Preliminary Vaporizer Related Sales of $25,638.00 in the Month of November

NEW YORK, NY–(Marketwired – Dec 15, 2014) – Easton Pharmaceuticals (OTC PINK: EAPH) Is pleased to announce details on its Vaporizer units progress with sales of $25,638.00 for the month of November.

Month end inventory on hand was shown at $10,670.00 for its vaporizer unit. Vaporizers were not Easton’s primary goal when it entered into the Medical Marijuana Industry. However, the company has been able to leverage its vaporizer unit to negotiate with Legal Marijuana Prescription Services Businesses.

Its first sale of a Vaporizer was made on the first day of its website launch and was for a ZEDS vaporizer unit. Since that date sales have been progressing at a steady pace, Cyber week provided an additional catalyst for sales in November. Currently the most popular brands have been the following units:

http://ecigmarkets.com/product/hebe-2-0/

The HEBE 2.0 is a robust vaporizing instrument featuring an intuitive temperature control system. It offers a wide-mouth heating chamber for easy loading and cleaning and features a durable and rugged rubberized exterior.

http://ecigmarkets.com/product/davinci-vaporizer/

The DaVinci Vaporizer combines a feature rich platform with rugged portability. Our most popular model in the DaVinci line, which is offered in a very appealing and popular black matte finish.

The company believes it has already received a good return on its conservative investments made on its vaporizer Initiative. Future sales cannot be accurately estimated but testing has shown that Vaporizer retail Location(s) in the Greater Toronto Area along with a New York City location would both be viable initiatives. The company believes utilizing these retail locations as multi purpose facilities in the selling of products and services such as Vaporizers, OTC products, and a Marijuana Prescription Service would be successful. This could lead towards its ultimate goal of acquiring a database of Legal Canadian Medical Marijuana patients which the company has initiated discussion on. Monetizing of these patients could be made in two ways which would include subscription fee’s alongside an administrative fee it would charge any currently Licensed Providers.

About Easton Pharmaceuticals

Easton Pharmaceuticals is a specialty pharmaceutical company involved in various pharmaceutical sectors and others industries such as medical marijuana. The Company previously developed and owned an FDA approved wound healing drug and currently owns topically-delivered drugs and therapeutic / cosmetic healthcare products focused on cancer and other health issues geared towards female sexual dysfunction, wound healing, pain, motion sickness and other conditions that are all in various stages of development. The company has ventured into the medical marijuana industry through an investment into AMFIL Technologies and their groZONE anti-bacterial system and maintains an exclusive option to purchase up to 49% in a medical marijuana grow-op business / facility which has received a letter to build from Health Canada. The company’s gel formulation is thought to be an innovative and unique transdermal delivery system that can in the future be adaptable in the delivery of Cannabidiol extracts.

For More Information Visit:
http://www.eastonpharmaceuticalsinc.com
http://www.ecigmarkets.com
http://finance.yahoo.com/q?s=eaph
https://twitter.com/eastonpharma

Safe Harbor
This news release may contain forward-looking statements or expressions within the meaning of the Private Securities Litigation Reform Act of 1995 (The “Act”). In particular, when certain words or phrases such as “hope”, “positive”, “anticipate,” “pleased,” “plan,” “confident that,” “believe,” “expect,” “possible” or “intent to” and similar conditional expressions are expressed, they are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Any investment made into Easton Pharmaceuticals would be classified as speculative and may contain risks. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company’s products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company’s financial reports and filings.

Contact:
Carla Pepe
Tel: +1(416) 619-0291
Tel: +1(347) 284-0192
Email: info@eastonpharmaceuticalsinc.com

0 94

Lexaria to Present Webcast on Thursday December 18

Lexaria, Corp. to Present at Cannabis Investor Webcast

Kelowna, BC / ACCESSWIRE / December 15, 2014 / Lexaria, Corp. (LXRP) (CSE:LXX) will be presenting at the Cannabis Investor Webcast on Thursday, December 18, 2014 at 2:00 PM ET (11 AM Pacific).

“We’re excited that Lexaria, Corp. has decided to present to our online audience of investors, analysts, entrepreneurs, media, and consumers,” said Derwin A. Wallace, Senior V.P. of Investor Webcast. “The online interactive webcast will assist Lexaria, Corp. in increasing its liquidity, awareness, and exposure.”

The Cannabis Investor Webcast includes presentations from privately-held and publicly-traded industry companies and industry professionals. Our presentation will be 30-minutes and followed by 15-minutes of Q&A. The Cannabis Investor Webcast is a great opportunity for the audience to research Lexaria without taking time-off from work, paying registration fees or incurring travel-related expenses.

“This is a great opportunity for Lexaria to use The Cannabis Investor Webcast as an online interactive platform to assist us in increasing awareness and exposure. I will give an overview of our company and its exciting new developments to everyone interested in their personal health and well-being,” states Chris Bunka, President of Lexaria Corp.

Investors, analysts, entrepreneurs, media, and consumers who want to learn more about our PoViva-brand Tea can attend the free online webcast by clicking on the link http://www.cannawebcast.com/ and visit the Registration Page. To view the recording of the webcast please click on this link Cannabis Investor Webcast Recordings one week after the presentation.

About Lexaria:
Lexaria’s shares are quoted in the USA with symbol LXRP and in Canada with symbol LXX. The company searches for projects that could provide potential above-market returns.

To learn more about Lexaria Corp. visit www.lexariaenergy.com.

Contact:
Lexaria Corp.
Chris Bunka
Chairman & CEO
(250) 765-6424

Forward-Looking Statements:
This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Access to capital, or lack thereof, is a major risk and there is no assurance that the Company will be able to raise required working capital. Current oil and gas production rates may not be sustainable and targeted production rates may not occur. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that the medical marijuana, CBD sector, or alternative health businesses will provide any benefit to Lexaria, or that the Company will experience any growth through participation in these sectors. There is no assurance that existing capital is sufficient for the Company’s needs or that it will need to attempt to raise additional capital. There is no assurance that and cannabidiol-based product will promote, assist, or maintain any beneficial human health conditions whatsoever. No statement herein has been evaluated by the Food and Drug Administration (FDA). PoViva products are not intended to diagnose, treat, cure or prevent any disease.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Source: Lexaria Corp.

 

0 153

Easton Pharmaceuticals Executes Letter of Intent and Provides Details on Green Patient Network’s Business Plan

TORONTO, ON–(Marketwired – Dec 12, 2014) – Easton Pharmaceuticals (OTC: EAPH) announces it has executed a letter of intent with Canadian Medical Marijuana Club Inc and initiated negotiations to enter the Legal Medical Marijuana prescription access business.

Easton is negotiating a first of its kind in the Canadian medical marijuana industry by having Green Patient Network offered to the public. Green Patient Network should see synergies that present itself from Easton’s Vaporizer customers and the overlap in users which can directly help reduce current patient acquisition costs. Any prospective patient wishing to become a legal Canadian Medical Marijuana Card holder and member can find great value in the services offered by becoming a member of Medical Marijuana Club / Green Patient Network(GPN). Current Market targeted scope will include the major metro area’s in the Canadian marketplace (Vancouver, Calgary and Toronto). In march 2014 there were approximately 40,000 Legal Medical Marijuana Prescription holders in Canada. (Source Health Canada) Currently it is believed that number has increased to 60,000-70,000 patients. Growth in the patient population is being hampered as potential marijuana patients find it is still not an open acceptable subject to discuss their needs with their healthcare provider. Some MMPR un-informed doctors will not easily prescribe Medical Marijuana to their patients due to undue scrutiny placed on them by Health Canada, the RCMP and other regulators.

These underserved patients who suffer from Autism, Epilepsy, Dementia, Diabetes, Glaucoma, Tourette Syndrome, Cancer, PTSD and other ailments are in search of services such as the one being negotiated as a supplement to their current plan of care.

What the Green Patient Network Service Provides :

– Provides Canadian patients looking to obtain legal access with specialized online physician consultations via tele health.

– Connects underserved patients with a trusted network of doctors who advocate working with Licensed Providers within the framework of Canada’s MMPR network.

– Marijuana Licensed Provider prescription management and Marijuana batch number tracking services. This removes the stress of patients having to worry about losing their prescription or having to monitor if any recall’s are made by their LP provider.

– Nursing support line for any patients/ Members who have an adverse reaction to any Marijuana related product.

- Pre Qualification Questionnaire that helps make the entire process easy to understand for the patient.

Costs of this service: membership dues for a single are $375 annually or $150 initial and $30 each monthly subscription model.

Easton Pharmaceuticals Plans to provide updates on these fast moving negotiations in the Legal Medical Marijuana prescription access business within the next 7 to 15 days.. These negotiations are in no way detracting from other negotiations that are being done in the Medical Marijuana space in the United States or other business segments which we plan to divulge within the next week to 10 days.

In other news Easton Pharmaceuticals plans to update its shareholders on prior partnerships made and progress made with AMFIL Technologies and its GrowZone joint venture. Its current adoption has been proceeding well and revenue recognition is slated for this quarter on shipments made within the second Quarter of 2015.

In other news Easton and / or its representatives plans on attending the upcoming Emerald Cup.

About Easton Pharmaceuticals

Easton Pharmaceuticals is a specialty pharmaceutical company involved in various pharmaceutical sectors and others industries such as medical marijuana. The Company previously owned an FDA approved wound healing drug and currently owns topically-delivered drugs and therapeutic / cosmetic healthcare products focused on cancer and other health issues geared towards female sexual dysfunction, wound healing, pain, motion sickness and other conditions that are all in various stages of development. The company has ventured into the potentially lucrative medical marijuana industry through an investment into AMFIL Technologies and their groZONE anti-bacterial system and the exclusive option to purchase up to 49% in a medical marijuana grow-op business / facility which has received a letter to build from Health Canada. The company’s gel formulation is thought to be an innovative and unique transdermal delivery system that can in the future be adaptable in the delivery of Cannabidiol extracts.

For More Information Visit:

http://www.eastonpharmaceuticalsinc.com

http://finance.yahoo.com/q?s=eaph

https://twitter.com/eastonpharma

Safe Harbor

This news release may contain forward-looking statements or expressions within the meaning of the Private Securities Litigation Reform Act of 1995 (The “Act”). In particular, when certain words or phrases such as “hope”, “positive”, “anticipate,” “pleased,” “plan,” “confident that,” “believe,” “expect,” “possible” or “intent to” and similar conditional expressions are expressed, they are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Any investment made into Easton Pharmaceuticals would be classified as speculative and may contain risks. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company’s products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company’s financial reports and filings.

Contact:
Carla Pepe
Tel: +1(416) 619-0291
Tel: +1(347) 284-0192
Email: info@eastonpharmaceuticalsinc.com